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cells, or formation of biofilm, and emer-
gence of antibiotic-resistant pathogens 
recalcitrant to treatment due to acquired 
resistance. Here, we report that a puri-
fied cranberry proanthocyanidin (cPAC) 
fraction potentiates the activity of a broad 
range of antibiotic classes against the 
opportunistic pathogens Escherichia coli, 
Proteus mirabilis, and Pseudomonas aer-
uginosa. cPAC was an effective potentiator 
against diverse bacterial lifestyles normally 
tolerant to antibiotics, such as biofilm bac-
teria, dormant cells, and in experimental 
models of chronic infections. Remark-
ably, when combined with tetracycline, 
cPAC was able to completely prevent 
the evolution of resistance in E. coli and 
P. aeruginosa. These results suggest that in 
combination with antibiotic therapy, cPAC 
has the potential to decrease the spread of 
antibiotic resistance and prolong the effec-
tiveness of currently available drugs.
Opportunistic pathogens colonize sur-
faces in healthcare settings, on indwelling medical devices, 
and on living tissues, leading to infections that must be treated 
with antibiotics. Two major factors complicate the effective-
ness of antibiotic treatments: i) antibiotic-resistant bacteria 
and ii) the formation of antibiotic-tolerant biofilms.[1] The 
latter sessile bacteria can withstand antibiotic doses up to thou-
sands of times higher than their planktonic counterparts,[2–4] 
due largely to the presence of tolerant and persister cells that 
remain dormant within the biofilm, ready to reinitiate growth 
when antibiotic concentrations decrease. Prolonged antibiotic 
treatment and high antibiotic doses necessitated by the recalci-
trant nature of such infections put patients’ health at risk and 
create a strong selective pressure for the evolution of antibiotic 
resistance.[2,3,5] In order to decrease the occurrence of antibiotic 
resistance and mitigate negative side effects brought on by high 
antibiotic doses, novel approaches to enhance the effectiveness 
of currently available antibiotics represent an attractive alterna-
tive to the search for new antibiotics. Exploiting natural mole-
cules with antibiotic-potentiating activities provides one such 
opportunity.
The American cranberry (Vaccinium macrocarpon L.) fruit 
and its derivatives have long been anecdotally reported as a 
natural remedy for urinary tract infections.[6,7] cPAC are con-
densed tannins that can hinder bacterial attachment to cel-
lular or biomaterial surfaces,[8–11] impair bacterial motility,[12–17] 
induce a state of iron limitation,[18] and interfere with quorum 
sensing.[19] Studies suggest that consumption of cranberry 
Antibiotic resistance is spreading at an alarming rate among pathogenic 
bacteria in both medicine and agriculture. Interfering with the intrinsic 
resistance mechanisms displayed by pathogenic bacteria has the 
potential to make antibiotics more effective and decrease the spread of 
acquired antibiotic resistance. Here, it is demonstrated that cranberry 
proanthocyanidin (cPAC) prevents the evolution of resistance to tetracycline 
in Escherichia coli and Pseudomonas aeruginosa, rescues antibiotic efficacy 
against antibiotic-exposed cells, and represses biofilm formation. It is shown 
that cPAC has a potentiating effect, both in vitro and in vivo, on a broad 
range of antibiotic classes against pathogenic E. coli, Proteus mirabilis, 
and P. aeruginosa. Evidence that cPAC acts by repressing two antibiotic 
resistance mechanisms, selective membrane permeability and multidrug 
efflux pumps, is presented. Failure of cPAC to potentiate antibiotics against 
efflux pump-defective mutants demonstrates that efflux interference is 
essential for potentiation. The use of cPAC to potentiate antibiotics and 
mitigate the development of resistance could improve treatment outcomes 
and help combat the growing threat of antibiotic resistance.
Antibiotic Resistance
1. Introduction
The global spread of antibiotic resistance is undermining dec-
ades of progress in fighting bacterial infections. Due to the 
overuse of antibiotics in medicine and agriculture, we are on 
the cusp of returning to a pre-antibiotic era in which minor 
infections can once again become deadly. Countering the fall 
in antibiotic efficacy by improving the effectiveness of currently 
available antibiotics is therefore an important goal. Antibiotic 
efficacy is limited by the expression of intrinsic tolerance mecha-
nisms such as production of antibiotic-tolerant and/or persister 
© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, 
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can prevent bacterial infections,[20–25] and one reports the 
combined effect of bulk cranberry derivatives (devoid of the 
proanthocyanidin fraction) and β-lactam antibiotics against 
a Gram-positive bacterium.[26] It has also been suggested that 
cPAC can inhibit biofilm formation and potentiate gentamicin 
against P. aeruginosa;[17] however, the potential for cPAC to 
interfere with the evolution of resistance to antibiotics or rescue 
the effectiveness of antibiotics has never been investigated. Fur-
thermore, no studies have explored the activity spectrum or the 
molecular mode of action of specific cranberry-derived fractions 
such as proanthocyanidins for the treatment of bacterial infec-
tions. Here, we report the ability of cPAC to thwart the evolu-
tion of resistance to tetracycline in E. coli and P. aeruginosa, and 
demonstrate the broad spectrum, antibiotic-potentiating activity 
of cPAC against various pathogenic Gram-negative bacteria, 
both in vitro and in vivo. We also show that cPAC is able to 
repress two important intrinsic antibiotic resistance mecha-
nisms: selective membrane permeability and multidrug efflux 
pump activity.
2. Results
2.1. cPAC Potentiates a Broad Range of Antibiotics In Vitro
We conducted screening assays with cPAC in combination with 
several classes of clinically approved antibiotics belonging to 
the World Health Organization’s list of essential medications.[27] 
Checkerboard microdilution analysis was performed using 
pathogenic strains of E. coli, P. mirabilis, and P. aeruginosa. 
We determined whether cPAC was able to potentiate the effec-
tiveness of antibiotics by calculating the fractional inhibitory 
concentration index (FICI). Figure 1A–C shows positive and/
or negative interactions between cPAC and antibiotics against 
bacterial pathogens. FICI values of ≤0.5 (indicated by the gray 
zone) demonstrate that cPAC potentiated the effectiveness of 
sulfamethoxazole (SMX), nitrofurantoin (NIT), gentamicin 
(GEN), kanamycin (KAN), tetracycline (TET), and azithromycin 
(AZT) to inhibit the growth of E. coli CFT073, P. mirabilis 
HI4320, and P. aeruginosa PA14 using up to 98% less antibiotic 
than that required in the absence of cPAC. cPAC also poten-
tiated trimethoprim (TMP) and fosfomycin (FOS) activities to 
inhibit the growth of P. mirabilis HI4320; 81% and 98% less 
antibiotic were needed, respectively, than in the absence of 
cPAC. In the case of P. aeruginosa strain PAO1, cPAC enhanced 
the efficiency of the antibiotics SMX, FOS, NIT, GEN, KAN, 
and AZT (Figure S1A, Supporting Information). The fact that 
cPAC potentiates a given antibiotic against one strain but not 
another (e.g., cPAC potentiates FOS against P. mirabilis HI4320 
but not against P. aeruginosa PA14 or E. coli CFT073) provides 
evidence that the effect is specific and that cPAC is not simply 
inactivating the antibiotic. It is not surprising that the FICI 
values for the two P. aeruginosa strains were different for some 
antibiotics as they had different MICantibiotic values.[28]
At concentrations required to potentiate antibiotic effi-
cacy, cPAC alone had no detectable growth inhibition activity 
against all four pathogenic strains (Figures S1B and S2A–C, 
Supporting Information). Given the ability of cPAC to poten-
tiate TMP or SMX alone, we investigated the interaction of 
cPAC with co-trimoxazole (the combination of SMX and TMP, 
commonly used to treat urinary tract infections and bacterial 
dysentery[27]). cPAC enhanced the synergistic efficacy of co-
trimoxazole, reducing the MIC up to 64-fold against P. mira-
bilis HI4320. In the case of P. aeruginosa PA14, combination of 
cPAC with co-trimoxazole decreased the MIC by 32-fold, which 
is significantly more effective than the potentiating combina-
tions of cPAC with TMP or SMX alone (Figure S3, Supporting 
Information). The fact that cPAC potentiates antibiotics, but 
does not act as an antibiotic on its own, suggests that treatment 
with cPAC is unlikely to create selective pressure for the evolu-
tion of resistance.
2.2. cPAC Prevents Re-Activation of Antibiotic-Exposed Cells
To investigate the inhibitory activity of cPAC against antibiotic-
exposed bacteria, a modified disk-diffusion test was performed. 
Figure 2A shows that following treatment with the bacterio-
static antibiotic tetracycline (Step 1: application of TET antibi-
otic disk), bacteria in the growth-inhibition zone were able to 
recover when a new disk impregnated with glucose replaced the 
TET disk (at Step 2). An analysis of bacterial re-activation based 
on the occurrence of colonies inside a typical inhibition/clear 
zone shows that the degree to which cells “re-activate” to form 
colonies differs depending on the presence or absence of cPAC. 
Replacement with a glucose-only disk (at Step 2) enhanced the 
re-activation of cells (i.e., bacterial lawn in previous inhibition 
zone), while a disk with a combination of cPAC and glucose 
showed no re-activation of antibiotic-exposed cells. There were 
no colonies observed close to the cPAC-only disk, and the size 
of the clear zone with the cPAC-only disk (at Step 2) was similar 
to the TET disk (Step 1) and the glucose+cPAC disk (Step 2). 
Since cPAC alone did not inhibit bacterial growth of this, or 
any other tested strains (Figures S1B,C and S2A–F, Supporting 
Information), it is probable that the clear zones around the 
cPAC-only and the glucose+cPAC disks result from synergy of 
cPAC with TET remnants, which is in agreement with a slightly 
smaller diameter, since lower concentrations of cPAC and TET 
should be present at the distal edge of the zone. Similar effects 
were observed with minocycline (MIN; Figure S4, Supporting 
Information) against E. coli CFT073. These results suggest that 
cPAC can prolong the efficacy of remnant antibiotic against 
antibiotic-exposed cells even after treatment has ceased.
2.3. cPAC Thwarts Evolution of Antibiotic Resistance
To understand the role of cPAC in effectively inhibiting the re-
activation of antibiotic-exposed cells, we analyzed the ability of 
cPAC to suppress evolution of resistance in E. coli CFT073 and 
P. aeruginosa PA14. As shown in Figure 2B,C, sequential pas-
saging on TET alone for 21 days resulted in 128-fold and 32-fold 
increases in MIC for E. coli CFT073 and P. aeruginosa PA14, 
respectively, while cPAC prevented the evolution of resistance 
in both strains when co-administered with TET. cPAC alone did 
not promote resistance in either strain. This result shows that 
cPAC can suppress the emergence of antibiotic resistance in 
bacteria.
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2.4. cPAC Potentiates In Vivo Activity of SMX
Our next goal was to investigate the potential of cPAC to 
enhance the efficacy of antibiotics against bacterial infections 
in vivo. To this end, we used the model host Drosophila mela-
nogaster infected with P. aeruginosa PA14, in which cPAC or 
SMX was administered alone or in combination. The median 
survival of the insects following infection was 138 h in the 
absence of treatment, but more than 225 h when cPAC and 
SMX were combined (Figure 3A). Survival of flies following 
combination therapy was significantly (χ2 = 3.88, df = 1, 
P < 0.05) higher than survival with SMX treatment alone. The 
median survival time of infected D. melanogaster treated with 
cPAC alone or SMX alone was 202 and 178 h, respectively 
(Figure 3A), which is not significantly (P > 0.05) different from 
the survival of untreated flies infected with P. aeruginosa PA14. 
The survival of uninfected D. melanogaster was similar to treat-
ment with cPAC or SMX alone (Figure S5A, Supporting Infor-
mation), which indicates that cPAC (at 50 µg mL−1) or SMX 
(at 256 µg mL−1) alone is safe for this animal.
To confirm that cPAC is able to potentiate antibiotics in more 
than one host, we also used the greater wax moth (Galleria 
mellonella) larvae killing model, in which cPAC or SMX was 
administered alone, or in combination, to larvae infected with a 
lethal dose of P. aeruginosa PA14. The median survival of infected 
and untreated larvae was 21 h, but increased to 47 h with the 
Adv. Sci. 2019, 6, 1802333
Figure 1. Potentiating interaction of cPAC with antibiotic results in growth inhibition. MICs were determined for the combination of cPAC with each 
antibiotic in vitro. Fractional inhibitory concentration index (FICI) for each combination are shown for A) E. coli CFT073, B) P. mirabilis HI4320, and C) P. 
aeruginosa PA14. A FICI of ≤0.5 is indicated by the gray shaded area. TMP: trimethoprim; SMX: sulfamethoxazole; FOS: fosfomycin; NIT: nitrofurantoin; 
GEN: gentamicin; KAN: kanamycin; TET: tetracycline; AZT: azithromycin.
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cPAC and SMX combination treatment. This is a significantly 
(χ2 = 14.3, df = 1, P < 0.005) longer survival time than the 36 h 
median survival time with SMX treatment alone (Figure 3B). 
The median survival of infected larvae with cPAC treatment 
alone was similar to the treatment of SMX alone (Figure 3B), 
which is in contrast to cPAC’s inability to act as an antibiotic at 
this concentration in vitro, or in the fly feeding model. As with 
the D. melanogaster feeding assay, there was no difference in sur-
vival curves of uninfected G. mellonella larvae with or without 
treatment of cPAC or SMX alone (Figure S5B, Supporting Infor-
mation). These results confirm that cPAC potentiates the activity 
of SMX in vivo, at the tested concentration of 50 µg mL−1 cPAC.
Adv. Sci. 2019, 6, 1802333
Figure 2. Synergistic effect of cPAC with TET for the inhibition of growth re-activation of antibiotic-exposed cells and prevention of the evolution of 
resistance. A) Detection of growth re-activation of antibiotic-exposed E. coli CFT073 cells using a modified disk-diffusion assay. Step 1: a TET antibi-
otic disk was placed on top of MHB-II agar. The dashed lines mark the diameter of the clear zone surrounding the TET disk. Step 2: the TET disks 
are replaced with a glucose alone, cPAC+glucose, or cPAC alone disk on the MHB-II agar plate. The diameter of the clear zone (CZ) and no colony 
formation inside the clear zone surrounding the cPAC+glucose disk indicate no re-activation of antibiotic-exposed cells after disk replacement at Step 
2 and colonies inside the inhibition zone (indicated by black arrow) surrounding the glucose disk indicate re-activation of antibiotic-exposed cells. 
The cPAC-only disk prevented re-activation of growth, most likely because of synergy with TET remnants. The images shown are only representative 
images of three independent experiments. Disk diameter: 6 mm. Emergence of antibiotic resistance in B) E. coli CFT073 and C) P. aeruginosa PA14 
during 21 serial passages in the presence of sub-MIC levels of TET compared to 400 µg mL−1 cPAC alone or its combination with 100 µg mL−1 cPAC.
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2.5. cPAC in Combination with an Antibiotic Impairs Biofilm 
Formation
To explore whether cPAC can impair the formation of biofilms 
during antibiotic treatment, monoculture bacterial biofilms 
were grown in microtiter plates in the presence of different con-
centrations of cPAC and SMX. As shown in Figure 4A–C, cPAC 
decreased biofilm formation of E. coli CFT073, P. mirabilis 
HI4320, and P. aeruginosa PA14. cPAC alone at 100 µg mL−1 
showed significant (P < 0.05) inhibition of monoculture bio-
films, which is consistent with other studies showing that cPAC 
or cranberry extracts can decrease bacterial adhesion.[8–11] 
Importantly, cPAC in combination with SMX had a significant 
(P < 0.01) inhibitory effect on the development of biofilms in a 
dose-dependent manner (Figure 4A–C; Figure S1D, Supporting 
Information). Untreated control biofilms were composed of 
viable cells (Figure 4D, in green) attached to the surface and 
forming dense microcolonies (Figure 4Di). SMX alone at tested 
concentrations had minimal effect on biofilms. However, 
treatment with cPAC and SMX in combination resulted in a 
decrease in the total density of attached biomass and viability 
when compared to untreated biofilms (Figure 4E,F). Interest-
ingly, the majority of the bacterial biomass was dead when 
treated with 512 µg mL−1 SMX in combination with cPAC 
(Figure 4Dviii,ix). If we presume that the few cells left alive in 
the presence of 512 µg mL−1 SMX and 50 µg mL−1 cPAC are 
dormant, capable of reactivating when the antibiotic threat has 
passed and forming a new biofilm, then increasing the concen-
tration of cPAC to 100 µg mL−1 was sufficient to eradicate these 
surviving cells. Because a combination of cPAC and SMX is 
more effective against biofilms than either compound is alone, 
these observations demonstrate that cPAC acts synergistically 
with SMX to reduce the ability of bacteria to form biofilms, and 
supports the hypothesis that cPAC contributes to the impair-
ment of dormant antibiotic-exposed cells.
2.6. Mechanisms by Which cPAC Potentiates Antibiotic Activity
To identify the mechanism(s) of action by which cPAC potenti-
ates antibiotic activity, we quantified the changes in bacterial cell 
outer membrane permeability using 1-N-phenylnapthylamine 
(NPN) as an indicator, which revealed that cPAC increases 
outer membrane permeability of bacterial cells (Figure 5A–C). 
Investigations into efflux pump activity using ethidium bro-
mide (EtBr) as a fluorescent indicator substrate showed that, 
in contrast to the decay in fluorescence observed in untreated 
cells (Figure 5D–F), cells treated with cPAC, or the efflux pump 
inhibitor carbonyl cyanide m-chlorophenylhydrazone (CCCP), 
remained fluorescent over time due to a failure to pump out 
EtBr (Figure 5D–F). These observations demonstrate that cPAC 
is able to inhibit multidrug resistance efflux pumps. To further 
investigate the interaction between cPAC and multidrug resist-
ance efflux pumps, we employed a systematic checkerboard 
MIC analysis of P. aeruginosa PA14 efflux pump mutants. 
The overexpression of efflux pump systems causes increased 
resistance to antibiotics compared to wild-type isolates while 
disruption of efflux pump protein components is associated 
with increased intracellular antibiotic accumulation and antibi-
otic susceptibility.[29] We show here that the ability of cPAC to 
potentiate TET activity correlates with efflux pump activity. The 
mutant strains with nonfunctioning efflux pumps were more 
susceptible to TET compared to the wild-type strain, such that 
addition of cPAC provided no further benefit for the potency of 
TET. Therefore, potentiation between cPAC and TET was not 
observed in efflux pump-nonfunctioning mutants (Figure 5G). 
This lack of TET potentiation correlates well with TET potentia-
tion by cPAC in the case of wild type P. aeruginosa PA14, which 
has functioning efflux pumps (Figure 1C). Interestingly, cPAC 
caused no significant damage to bacterial cell membranes 
(Figure 5H), compared to significant (P < 0.05) membrane dis-
ruption by cetyl trimethylammonium bromide (CTAB), a cell 
Adv. Sci. 2019, 6, 1802333
Figure 3. In vivo synergistic effect of cPAC with antibiotic for the protection of insect models. A) In vivo synergy between sulfamethoxazole (SMX) and 
cPAC was tested in a D. melanogaster fly feeding model. Flies (N = 30 per experimental group) were infected orally with P. aeruginosa PA14 cells and 
maintained on agar containing SMX in combination with cPAC. Results represent measurements from experiments performed in triplicate (*, P < 0.05, 
log-rank (Mantel–Cox) test). B) In vivo synergy between SMX and cPAC was tested in a G. mellonella larvae infection model. G. mellonella larvae were 
infected with a lethal dose of P. aeruginosa PA14 cells. These infected G. mellonella larvae (N = 20 per experimental group) were injected a second time 
at the same infection site with cPAC or SMX, alone or in combination at 3 h post. Results represent measurements from two independent experiments 
performed in duplicate (*, P < 0.005, log-rank (Mantel–Cox) test).
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membrane–disrupting agent, suggesting that outer membrane 
permeabilization and target specific efflux pump inhibition are 
achieved by cPAC without altering cell membrane integrity.
2.7. cPAC Interacts with Efflux Pump Components In Silico
To understand how cPAC is able to inhibit the activity of 
efflux pumps, we performed in silico docking analyses using 
the efflux pump protein complexes AcrAB–TolC of E. coli, and 
MexAB–OprM of P. aeruginosa, with the A-type dimeric cPAC 
molecule as the test ligand. Ligand-binding domains of AcrAB–
TolC and MexAB–OprM efflux pump components exhibit 
sufficient space to accommodate the cPAC molecule with an 
average volume of 497.1 Å3 (Table S1, Supporting Informa-
tion). We tested structural in silico interactions of cPAC with 
the exit duct, adapter, and transporter components of the efflux 
pumps (Figure 6A; Figure S6A–G, Supporting Information). 
Molecular docking of cPAC with the exit duct complex predicts 
that cPAC favorably binds at the equatorial domain of the TolC 
Adv. Sci. 2019, 6, 1802333
Figure 4. Effect of cPAC alone and in combination with SMX on biofilm formation of A) E. coli CFT073, B) P. mirabilis HI4320, and C) P. aeruginosa 
PA14. The graphs present normalized biofilm levels (OD570/cell OD600) at subinhibitory concentrations of SMX. Statistically significant differences are 
indicated for each sample treated with cPAC and SMX compared to the control (sample treated with the corresponding concentration of SMX alone) 
(**, P < 0.01; *, P < 0.05; two-way ANOVA) and for samples treated with cPAC plus SMX compared to the sample treated with the same concentration 
of cPAC without SMX (*, P < 0.05; two-way ANOVA). D) Confocal microscopy images of P. aeruginosa PA14 biofilms grown with or without cPAC and/
or SMX at sub-MICs. Green color cells represent viable cells with intact membranes and red color cells are dead cells. Each representative image was 
selected from experiments performed in triplicates. E) Biofilm biomass as a percentage of untreated biomass, and F) percentages of live cells present 
in each treatment were quantified from confocal microscopy images. In all confocal microscopy images, red and green axis lengths are 100 µm, and 
the blue z-axis length is 10 µm.
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Figure 5. Mechanisms of antibiotic potentiation by cPAC. cPAC-mediated NPN uptake in A) E. coli CFT073, B) P. mirabilis HI4320, and C) P. aeruginosa 
PA14. Bacterial cells were pretreated with cPAC or gentamicin (Gen) for NPN uptake. Control represents NPN fluorescence in the presence of only cPAC 
without bacteria. Inhibition of multidrug efflux pump by cPAC or the known efflux pump inhibitor CCCP in D) E. coli CFT073, E) P. mirabilis HI4320, and F) P. 
aeruginosa PA14. Control represents untreated bacteria. G) MICs were determined for the combination of cPAC with TET in vitro. FICI values for cPAC+TET 
combination are shown for efflux pump mutants of P. aeruginosa PA14: mexL− (overexpressing MexJK-OprM), nfxB− (overexpressing MexCD-OprJ), 
nfxC− (overexpressing MexEF-OprN), nalC− (overexpressing MexAB-OprM), mexA− (nonfunctioning MexAB-OprM), and oprM− (nonfunctioning 
MexAB-OprM, MexJK-OprM, and MexXY-OprM). A FICI index of ≤0.5 is indicated by the gray shaded area. H) Effect of cPAC on cell membrane 
integrity. Cells of each strain were pretreated separately with cPAC or the cell membrane disrupting agent CTAB. The ratio of green to red fluorescence 
was normalized to that of the untreated control and expressed as a percentage of the control. All assays were repeated independently three times 
(* P < 0.05; Student’s t-test).
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exit duct (Figure 6A) and coiled-coil domain of the OprM exit 
duct (Figure S6A–C, Supporting Information). The molecular 
docking analyses also predict that cPAC can form hydrogen 
bonds with amino acid residues (N274, A279, and R620) pre-
sent in the distal substrate-binding pocket of AcrB that are 
critical for antibiotic/substrate binding, transportation to the 
Adv. Sci. 2019, 6, 1802333
Figure 6. Molecular docking analysis of cPAC in the AcrAB–TolC efflux pump. A) Complete side view with ribbon representation of docked complexes of 
efflux pump proteins with A-type cPAC molecule (a dimeric form of epicatechin), visualized along the Gram-negative cell membrane plane (OM, outer 
membrane; PP, periplasmic space; and IM, inner membrane). The inset views show the electron density map (2F0–Fc) of cPAC in binding sites of 
multidrug efflux pump exit duct, adapter, and transporter proteins. The amino acid residues around each binding site are depicted and all possible 
hydrogen bonds are shown using green lines. The ribbon representation of tripartite efflux pump components are color-coded: TolC exit duct (pink), 
AcrA adapter (gold) and AcrB transporter (blue). B) The AcrB monomer with inset views shows docking of cPAC molecule (salmon) to the distal 
binding pocket in the co-crystal structure of AcrB–MIN complex (yellow color carbons represent MIN molecule as found in the highest resolution 
crystal structure, PDB 4U8Y). C) Molecular docking analysis of different efflux pump substrates (yellow) binding at the distal binding pocket of AcrB 
transporter. D) The inset views show the optimum binding position of cPAC (salmon) and substrate (yellow) at the distal binding pocket of AcrB. The 
docking models of nonpotentiated antibiotics are highlighed with a dashed box.
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exit duct, and proper functioning of the entire efflux pump 
assembly (Figure 6A). cPAC showed the highest affinity for 
AcrB and MexB efflux pump components, with −9.9 and 
−9.6 kcal mol−1 binding energies, respectively (Table S1, 
Supporting Information).
A diverse range of antibiotics are pumped out by AcrAB–
TolC. However, only the co-crystal structures of MIN and dox-
orubicin binding to the active site of AcrB are reported.[30] To 
compare the binding of cPAC to that of a well-characterized 
efflux pump substrate, we docked cPAC to the distal binding 
pocket of the AcrB periplasmic porter domain co-crystallized 
with MIN, and found that cPAC and MIN bound to the same 
furrow of the distal substrate binding pocket (Figure 6B). We 
separately examined the predicted docking of the AcrB sub-
strates FOS, TMP, NIT, TET, SMX, and GEN in the absence and 
presence of cPAC (Figure 6C,D). All tested substrates bound to 
the AcrB–cPAC complex, specifically, in the same furrow of the 
distal binding pocket in which MIN binds (Figure 6C). Inter-
estingly, the binding position of FOS and TMP was unaffected 
by the presence of cPAC (Figure 6D), which is in agreement 
with the inability of cPAC to potentiate FOS or TMP against 
E. coli in vitro (Figure 1A). In contrast, we observed different 
binding conformations of the potentiated antibiotics NIT, TET, 
SMX, and GEN in the presence of cPAC compared to that in 
the absence of cPAC (Figure 6C,D). This suggests that binding 
of cPAC in the distal binding pocket leads to efflux inhibition 
by interfering with the preferred binding position of the poten-
tiated antibiotics. Finally, we confirmed that the binding confor-
mation of cPAC in the distal binding pocket of AcrB is similar 
to that of known efflux pump inhibitors (Figure S7A–F, Sup-
porting Information), which supports the hypothesis that cPAC 
acts as a potent efflux pump inhibitor.
3. Discussion
Tetracycline resistance is a well-documented phenomenon 
caused by efflux pump activity and the evolution of acquired 
antibiotic resistance.[31] We discovered that in the presence of 
cPAC, the acquisition of resistance in E. coli and P. aeruginosa 
following TET treatment is completely abrogated. cPAC’s ability 
to interfere with intrinsic resistance mechanisms is therefore 
able to suppress the typically inevitable, long-term evolution of 
acquired antibiotic resistance.
We have shown that cPAC potentiates the in vitro activity of 
a range of antibiotic classes against the opportunistic human 
pathogens E. coli, P. mirabilis, and P. aeruginosa. This potentia-
tion also occurs in vivo, at least with the antibiotic SMX. cPAC 
is an especially promising antibiotic-potentiating agent because 
it does not exhibit antimicrobial activity of its own. Agents 
that do not negatively affect the viability of bacterial patho-
gens are less likely to promote resistance than conventional 
antibiotics[32–34] and are, therefore, especially well suited for 
combination treatment with antibiotics. Accordingly, we have 
not observed any evolution of resistance to cPAC.
Biofilms can lead to chronic bacterial infections and are 
commonly associated with antibiotic treatment failure.[35,36] 
The presence of persister and antibiotic-tolerant cells is closely 
linked to biofilm formation,[5] and also plays an important role in 
the recalcitrance of chronic infections. The antiquorum sensing 
activity of a cranberry proanthocyanidin fraction alone[19] and 
in combination with ciprofloxacin[37] has been reported. As 
quorum sensing is required for normal biofilm formation, this 
agrees with our observations that cPAC in combination with 
antibiotic substantially represses biofilm formation. Further-
more, we propose that it is the ability of cPAC to target not only 
actively metabolizing cells, but also dormant antibiotic-exposed 
cells that enable cPAC to potentiate antibiotic efficacy against 
biofilms.
The intrinsic antibiotic resistance mechanisms of bacte-
rial cells are naturally occurring phenomena found in bacte-
rial species that complicate antibiotic treatments. For instance, 
P. mirabilis has intrinsic resistance to NIT and TET, and 
P. aeruginosa has intrinsic resistance to multiple antibiotic 
classes including aminoglycosides, β-lactams, quinolones, and 
polymyxins.[38,39] The intrinsic antibiotic resistance mechanisms 
include selective outer membrane permeability, poor antibiotic 
transport, and active multidrug efflux.[40,41] Among resistance– 
nodulation–division family efflux pumps, AcrAB–TolC[42,43] and 
MexAB–OprM[44] are well known for their importance in bac-
terial survival and intrinsic antibiotic resistance. Our in silico 
analysis predicts that the A-type dimeric cPAC molecule (which 
is the most common terminating unit of the cPAC fraction[45]) 
can occupy the ligand-binding pocket of the AcrB transporter 
in E. coli and MexB transporter of P. aeruginosa.[43,44,46] Mole-
cular docking calculations indicate that of all the antibiotics 
tested against E. coli, the two nonpotentiated antibiotics adopt 
the same position in the distal binding pocket in the presence 
and absence of cPAC. In contrast, the potentiated antibiotics 
are predicted to take a different binding position in the pres-
ence of cPAC, which would hinder their efflux from the cell. 
Exposure to cPAC enhanced membrane permeabilization and 
decreased efflux pump activity in all tested wild-type bacteria 
in vitro. The failure of cPAC to potentiate antibiotic activity in 
efflux pump-defective mutants supports a model where the spe-
cific effect cPAC has on efflux is essential for the observed anti-
biotic potentiating activity. Inactivation of efflux pump activity 
has previously been shown to have a negative impact on biofilm 
formation[47] and pathogenicity[48] in Gram-negative bacteria. 
This is consistent with our observations that in the presence of 
cPAC, biofilm formation is decreased. Overall, this study pro-
vides a proof of concept and a starting point for investigating 
the molecular mechanism of the reported efflux pump inhibi-
tion in bacteria by cPAC.
Insect animal models have a relatively evolved antimicro-
bial defense system and are thus often used to generate infor-
mation relevant to the mammalian infection process.[49,50] 
In both infection models used in this study, cPAC at a dose 
of 50 µg mL−1 was sufficient to potentiate the activity of the 
tested antibiotic and significantly increase survival rates of 
the animals during infection with P. aeruginosa. These in vivo 
studies provide a promising outlook for the potential future 
development of cPAC as an antibiotic-potentiating agent in 
higher organisms; however, a few studies report on the safety 
of cPAC to human cells[51] or its bioavailability and the rate 
of clearance in animals.[52] Thus, further work is needed to 
verify the efficacy and safety of the combination treatment in 
an in vivo mammalian (e.g., mouse) model. Encouragingly, 
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our data show that cPAC is able to enhance the efficacy of 
a broad spectrum of antibiotics. The ability to potentiate the 
action of antibiotics in a patient could improve treatment 
outcomes and hinder the emergence of antibiotic-resistant 
infections.
4. Experimental Section
Bacterial Strains, Growth Conditions, and Cranberry Proanthocyanidin: 
Opportunistic bacterial pathogens were used in this study: E. coli strain 
CFT073 (ATCC 700928), P. mirabilis HI4320,[53] P. aeruginosa PAO1 (ATCC 
15692), and P. aeruginosa PA14 (UCBPP-PA14).[54] Mutant strains of P. 
aeruginosa PA14 were used in this study: mexL− (overexpressing MexJK-
OprM),[55] nfxB− (overexpressing MexCD-OprJ),[55] nfxC− (overexpressing 
MexEF-OprN),[56] nalC− (overexpressing MexAB-OprM),[55] mexA−  
(nonfunctioning MexAB-OprM),[55] and oprM− (nonfunctioning MexAB-
OprM, MexXY-OprM, and MexJK-OprM).[55] Pure stock cultures were 
maintained at −80 °C in 30% (v/v) frozen glycerol solution. Starter 
cultures were prepared by streaking frozen cultures onto lysogeny broth 
agar (LB broth contained 10 g L−1 tryptone, 5 g L−1 yeast extract, and 
5 g L−1 NaCl, supplemented with 1.5% (w/v) agar (Fisher Scientific, 
ON, Canada)). After overnight incubation at 37 °C, a single colony was 
inoculated into 10 mL of Mueller–Hinton broth adjusted with Ca2+ and 
Mg2+ (MHB-II; Oxoid, Fisher Scientific Canada) and the culture was 
incubated at 37 °C on an orbital shaker at 200 rpm for a time length 
specific to each experiment. LB broth was used for bacterial culture in all 
experiments unless otherwise specified. The purified cranberry-derived 
proanthocyanidin (cPAC, 93% proanthocyanidins, 7% anthocyanins, 
and flavonoids monomers) was obtained from Ocean Spray Cranberries 
Inc. The supplier prepared the sample according to well-established 
methods[11,57] by enriching from cranberry fruit juice extract. A dry 
powder of cPAC was solubilized in deionized water and sterilized by 
filtration (0.22 µm polyvinylidene fluoride (PVDF) membrane filter).
Determination of MICs: MICs were determined by preparing twofold 
serial dilutions of cPAC, and antibiotics in MHB-II broth. A range of 
concentrations of the antibiotics (0.0003–1024 µg mL−1) was chosen 
due to their known potency against all four bacterial strains. Bacterial 
growth was assessed by i) monitoring the cell growth (observed as a 
pellet and turbidity) in the wells[58] ii) monitoring the optical density of 
the cell suspension in each well at 600 nm (OD600), and iii) using the 
resazurin microtiter plate assay.[59] Additional details can be found in the 
Supporting Information.
In Vivo Infection Assay Using D. Melanogaster Flies: Fruit flies 
(D. melanogaster) were infected orally in fly feeding assay in which flies 
were anesthetized, starved of food and water for several hours, and 
separated into vials containing filter paper disks inoculated with freshly 
grown P. aeruginosa PA14, as well as 5% sucrose agar (sterile) with and 
without 50 µg mL−1 cPAC alone or in combination with 256 µg mL−1 
SMX. Post infection mortality of flies was monitored daily for 14 days, 
with each treatment tested twice in triplicate. Additional details can be 
found in the Supporting Information.
In Vivo Infection Assay Using Galleria Mellonella Larvae: Twenty 
G. mellonella larvae were injected with active cultures of P. aeruginosa 
per treatment. All injected larvae were incubated in Petri dishes at 28 °C 
under 30% relative humidity in the dark, and the number of dead larvae 
was scored daily post infection. A larva was considered dead when it 
displayed no vital signs in response to touch, followed by increased 
melanization. Additional details are given in the Supporting Information.
Biofilm Assays: Biofilm formation was quantified using the standard 
microtiter plate model[60] and crystal violet staining, the details of which 
are described in Appendix S1 (Supporting Information). For biofilm 
imaging and analysis, biofilms were grown for 16 h at 37 °C under 
static conditions, after which planktonic cells were removed by rinsing. 
The cell-membrane impermeable fluorescent stain TOTO-1 (Thermo 
Fisher) and membrane permeable stain SYTO 60 (Thermo Fisher) 
were added to final working concentrations of 2 × 10−6 and 10 × 10−6 m, 
respectively.[61] Biofilms were imaged as z-stacks using a 63× objective 
on a Zeiss 800 confocal laser scanning microscope and rendered such 
that living cells are colored green, and dead cells are colored red as 
described in the Supporting Information.
Modified Disk-Diffusion Assay: A modified disk-diffusion assay[62] was 
used to detect recovery of antibiotic-exposed cells. This modified disk-
diffusion assay was conducted in two steps, where Step 1 was similar 
to classical disk-diffusion assay and Step 2 was slightly modified. 
Briefly, an overnight bacterial culture (MHB-II broth, 37 °C, 200 rpm) 
was diluted into fresh MHB-II broth to 106 CFU mL−1 and plated on 
MHB-II agar plate. Step 1: commercially available TET 30 µg or MIN 
30 µg antibiotic disk (Thermo Scientific Oxoid, Fisher Scientific, 
Canada) was placed on top of the inoculated agar surface and the 
plate was incubated at 37 °C for 18 h. Custom disks were prepared 
using sterile blank disks (Thermo Scientific Oxoid, Fisher Scientific, 
Canada) supplemented with 400 µg glucose or 400 µg cPAC with or 
without 400 µg glucose and left to dry at room temperature. Step 2: 
The antibiotic disk was carefully replaced with custom disks containing 
glucose or cPAC or their combination, and the plate was incubated at 
37 °C for an additional 18 h.
Emergence of Resistance Analysis: For characterization of in vitro 
resistance evolution by standard sequential passaging technique,[63,64] 
E. coli CFT073 and P. aeruginosa PA14 cells were grown to 
exponential phase in MHB-II at 37 °C. MICs were determined by 
preparing twofold serial dilutions in 96-well microtiter plates. Each 
well was inoculated with the desired bacterial strain, and the plate was 
incubated at 37 °C for 18 h under static conditions. Bacterial growth 
was assessed by i) monitoring the cell growth (observed as a pellet 
and turbidity) in the wells[58] and ii) monitoring the optical density 
of the cell suspension in each well at 600 nm (OD600nm). Bacterial 
suspension from sub-MIC (0.5 × MIC) of TET or cPAC or cPAC+TET 
combination was used to prepare the inoculum for the next day MIC 
experiment by diluting it to a final concentration of ≈106 CFU mL−1 
in MHB-II. This was repeated for 21 passages, and the ratio of the 
MIC obtained during each day relative to the MIC at 0 day (first 
time exposure) was determined. The data were expressed as relative 
fold increase in MIC with each day or passage. Experiments were 
performed with biological replicates.
Membrane Permeabilization and Membrane Integrity Assays: The 
outer membrane permeabilization activity of cPAC was determined by 
the NPN (Sigma-Aldrich, Canada) assay,[65] with some modifications. 
Overnight bacterial cultures were diluted 1:1 in MHB-II medium 
to a final volume of 10 mL, with or without supplementation of 
cPAC or GEN (positive control), and grown to an OD600 of 0.5–0.6 
(37 °C, 200 rpm). The cells were harvested, washed, resuspended 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer 
containing 1 × 10−3 m N-ethylmaleimide (NEM; Sigma-Aldrich, 
Canada). Aliquots were mixed with NPN to a final concentration of 
10 × 10−6 m (in cell suspension), and fluorescence was measured using 
the microplate reader (excitation: 350 nm; emission: 420 nm). The 
BacLight kit (L-13152; Invitrogen, Life Technologies Inc., Canada) was 
used to assess cell membrane damage,[66] with fluorescence readings 
from samples normalized to the values obtained from the untreated 
control to determine the ratio of membrane-compromised cells to 
cells with intact membranes. Details can be found in the Supporting 
Information.
EtBr Efflux Assay: To assess the effect of cPAC on the inhibition of 
the proton motive force–driven multidrug efflux pump, an EtBr efflux 
assay was performed.[67] An overnight-grown culture of each strain 
was diluted 1:100 in MHB-II broth to a final volume of 10 mL and was 
grown to an OD600 of 0.8–1.0 (at 37 °C, 150 rpm). Cells were loaded in 
polystyrene microcentrifuge tubes (2 mL) and mixed with 5 × 10−6 m EtBr 
and cPACs at 25% of their MIC or a 100 × 10−6 m concentration of the 
proton conductor CCCP (Sigma-Aldrich Canada) as a positive control. 
Replica tubes that did not receive cPACs or proton conductor served as 
negative controls. The tubes were incubated for 1 h (37 °C, 150 rpm). 
The inoculum then was adjusted to an OD600 of 0.4 with MHB-II broth 
containing 5 × 10−6 m EtBr, and 2 mL of aliquot of this mixture was 
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pelleted (5000 × g, 10 min, 4 °C). The pellets were incubated on ice 
immediately, resuspended in 1 mL of MHB-II, and aliquoted (200 µL) 
into a polystyrene 96-well, black, clear-bottom plate (Corning, Fisher 
Scientific Canada). EtBr efflux from the cells was monitored at room 
temperature using the microplate reader (excitation wavelength 530 nm; 
emission wavelength, 600 nm). Readings were taken at 5 min intervals 
for 1 h to monitor efflux pump activity. The background fluorescence of 
the medium was subtracted from all measurements, and the assay was 
repeated independently in triplicate.
In Silico Docking Analysis: 3DLigandSite server was used to predict 
ligand binding sites on targeted protein structures using an automated 
method by searching a structural library to identify homologous 
structures with bound ligands.[68] These bound ligands were 
superimposed onto the targeted protein structure to predict a ligand-
binding site. In silico docking was performed using the Autodock Vina 
tool without the incorporation of water molecules.[69] In silico docking 
analysis by Autodock Vina was compared with SwissDock web service 
(http://www.swissdock.ch/) to confirm the accuracy and robustness of 
predicted docking complexes. The ligand docking methods are described 
in the Supporting Information.
Statistical Analysis: Where indicated, a two-tailed Student’s t-test 
(P < 0.05) was used to determine whether the presence of cPAC 
resulted in a significant difference compared to levels for the control. 
A two-way analysis of variance (ANOVA), followed by Sidak’s multiple 
comparison, was used for biofilm assays to analyze statistical 
significance of the difference in biomass. Fruit fly survival curves were 
prepared using GraphPad Prism 6 (GraphPad Software, Inc., San Diego, 
CA) to perform a statistical log–rank (Mantel–Cox) test. Throughout the 
text, all of the changes (increase or decrease) reported were statistically 
significant. Statistically nonsignificant values were not mentioned in 
the text.
Full Methods: Detailed procedures of all methods are available in the 
Supporting Information.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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